These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Immunohistochemical analysis of pleomorphic lobular carcinoma: higher expression of p53 and chromogranin and lower expression of ER and PgR. Radhi JM Histopathology; 2000 Feb; 36(2):156-60. PubMed ID: 10672061 [TBL] [Abstract][Full Text] [Related]
23. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer. Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205 [TBL] [Abstract][Full Text] [Related]
24. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205 [TBL] [Abstract][Full Text] [Related]
25. Clinicopathological characteristics of estrogen receptor-beta-positive human breast cancers. Miyoshi Y; Taguchi T; Gustafsson JA; Noguchi S Jpn J Cancer Res; 2001 Oct; 92(10):1057-61. PubMed ID: 11676856 [TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma. Correlation with histopathology and DNA flow cytometry. Helin HJ; Helle MJ; Kallioniemi OP; Isola JJ Cancer; 1989 May; 63(9):1761-7. PubMed ID: 2649227 [TBL] [Abstract][Full Text] [Related]
27. Application of quantitative analysis to biologic profile evaluation in breast cancer. Querzoli P; Ferretti S; Albonico G; Magri E; Scapoli D; Indelli M; Nenci I Cancer; 1995 Dec; 76(12):2510-7. PubMed ID: 8625078 [TBL] [Abstract][Full Text] [Related]
28. Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in breast carcinoma by real-time polymerase chain reaction. Iwao K; Miyoshi Y; Egawa C; Ikeda N; Tsukamoto F; Noguchi S Cancer; 2000 Oct; 89(8):1732-8. PubMed ID: 11042568 [TBL] [Abstract][Full Text] [Related]
29. Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR. Charpin C; Bonnier P; Khouzami A; Vacheret H; Andrac L; Lavaut MN; Allasia C; Piana L Anticancer Res; 1992; 12(3):591-7. PubMed ID: 1352440 [TBL] [Abstract][Full Text] [Related]
30. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype. Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807 [TBL] [Abstract][Full Text] [Related]
31. Ras p21 immunostaining in early stage squamous cervical carcinoma: relationship with lymph nodal involvement and 72 kDa-metalloproteinase index. Garzetti GG; Ciavattini A; Lucarini G; Goteri G; Nictolis MD; Romanini C; Biagini G Anticancer Res; 1998; 18(1B):609-13. PubMed ID: 9568185 [TBL] [Abstract][Full Text] [Related]
32. p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment. Caleffi M; Teague MW; Jensen RA; Vnencak-Jones CL; Dupont WD; Parl FF Cancer; 1994 Apr; 73(8):2147-56. PubMed ID: 8156519 [TBL] [Abstract][Full Text] [Related]
33. Bcl-2 with loss of apoptosis allows accumulation of genetic alterations: a pathway to metastatic progression in human breast cancer. Sierra A; Castellsagué X; Escobedo A; Lloveras B; García-Ramirez M; Moreno A; Fabra A Int J Cancer; 2000 Mar; 89(2):142-7. PubMed ID: 10754491 [TBL] [Abstract][Full Text] [Related]
34. Expression of metastasis-associated genes h-mts1 (S100A4) and nm23 in carcinoma of breast is related to disease progression. Albertazzi E; Cajone F; Leone BE; Naguib RN; Lakshmi MS; Sherbet GV DNA Cell Biol; 1998 Apr; 17(4):335-42. PubMed ID: 9570150 [TBL] [Abstract][Full Text] [Related]
35. Value of measuring hormone receptor levels of regional metastatic carcinoma of the breast. Butler JA; Trezona T; Vargas H; State D Arch Surg; 1989 Oct; 124(10):1131-4; discussion 1134-5. PubMed ID: 2802974 [TBL] [Abstract][Full Text] [Related]
36. The correlation between estrogen and progesterone receptors and some clinical and pathological features in human breast cancer. Caldarola L; Volterrani P; Lai M; Vigezzi P; Gaglia P Ital J Surg Sci; 1985; 15(4):329-33. PubMed ID: 3830952 [TBL] [Abstract][Full Text] [Related]
37. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. Kuukasjärvi T; Kononen J; Helin H; Holli K; Isola J J Clin Oncol; 1996 Sep; 14(9):2584-9. PubMed ID: 8823339 [TBL] [Abstract][Full Text] [Related]
38. Comparison of Syndecan-1 Immunohistochemical Expression in Lobular and Ductal Breast Carcinoma with Nodal Metastases. Miše I; Vučić M Anal Cell Pathol (Amst); 2018; 2018():9432375. PubMed ID: 30151336 [TBL] [Abstract][Full Text] [Related]
39. Expression of ras p21 oncoprotein in normal and neoplastic human endometrium. Scambia G; Catozzi L; Benedetti-Panici P; Ferrandina G; Battaglia F; Giovannini G; Distefano M; Pellizzola D; Piffanelli A; Mancuso S Gynecol Oncol; 1993 Sep; 50(3):339-46. PubMed ID: 8406198 [TBL] [Abstract][Full Text] [Related]